First-Line Treatments for Extensive-Stage Small-Cell Lung Cancer With Immune Checkpoint Inhibitors Plus Chemotherapy: A Network Meta-Analysis and Cost-Effectiveness Analysis

BACKGROUND: Immune checkpoint inhibitors (ICIs) plus chemotherapy were unlikely to be considered cost-effective compared with chemotherapy as the first-line treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) in China due to its high costs. However, the cost-effectiveness of...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Shuo, Wang, Xinchen, Zhang, Yue, Zhang, Boyuan, Shang, Fangjian, Guo, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807476/
https://www.ncbi.nlm.nih.gov/pubmed/35127468
http://dx.doi.org/10.3389/fonc.2021.740091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807476/
https://www.ncbi.nlm.nih.gov/pubmed/35127468
http://dx.doi.org/10.3389/fonc.2021.740091

Ejemplares similares